Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.

Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.

Manufacturers will face the “biggest PBM ever” in price negotiations for pharmacy benefit drugs as a result of the collaboration between the two pharmacy benefit managers.

Start with the trial’s primary objective and then figure out which RWD sources could help inform that outcome, experts say at Duke-Margolis meeting; however, design and underlying objectives of Novo Nordisk’s real-world use of trial of Ozempic have the FDA’s Robert Temple suggesting success will be a ‘longshot.’